Article

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trial

2026-05-15

Abstract excerpt

<title>Abstract</title> <p> Background Patients with unresectable locally advanced or metastatic solid tumors have limited therapeutic options. Antibody-guided allogeneic natural killer (NK) cell therapy represents a novel immunotherapeutic strategy to enhance tumor targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigens such as 5T4. Objective To evaluate the safety, t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6f11c694-da58-5ff1-9262-015747583b16
DOI: 10.21203/rs.3.rs-9597110/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trialDOI 10.21203/rs.3.rs-9597110/v1Read

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trialSemantic proximity Read

Principles and Current Clinical Landscape of Multispecific Antibodies against CancerSemantic proximity Read

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the futureSemantic proximity Read

Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targetingSemantic proximity Read

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedsideSemantic proximity Read

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challengesSemantic proximity Read

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib studySemantic proximity Read

A Novel Feeder cell based on 4-1BBL and Membrane-bound IL-21/ IL-15 Induce Highly Expansion and Anti-tumor Effect of Natural Killer CellsSemantic proximity Read